grade
pharmaceutical primary standard
API family
furosemide
manufacturer/tradename
USP
mp
267 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
Nc1cc(Cl)c(cc1C(O)=O)S(N)(=O)=O
InChI
1S/C7H7ClN2O4S/c8-4-2-5(9)3(7(11)12)1-6(4)15(10,13)14/h1-2H,9H2,(H,11,12)(H2,10,13,14)
InChI key
QQLJBZFXGDHSRU-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Furosemide Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 4-氯-5-氨磺酰邻氨基苯甲酸
hcodes
Hazard Classifications
Aquatic Chronic 2
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
pcodes
[Determination of furosemide and its metabolic products in plasma and urine by high performance liquid chromatography and clinical application].
Y Miwa et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 108(11), 1087-1092 (1988-11-01)
D E Smith et al.
Drug metabolism and disposition: the biological fate of chemicals, 8(5), 337-342 (1980-09-01)
The objectives of this study were to qualitatively and quantitatively compare the metabolism, pharmacokinetics, and bioavailability of furosemide in healthy volunteers after intravenous and oral administration. We also determined the plasma protein binding of furosemide in vivo after iv administration.
G M Hanna et al.
Journal of AOAC International, 76(3), 526-530 (1993-05-01)
A simple, specific, and accurate proton nuclear magnetic resonance (1H-NMR) spectroscopic method has been developed for the identification and assay of furosemide and its degradation product, 4-chloro-5-sulfamoylanthranilic acid (CSA), in tablets and injections. Dissolution of the sample in D2O-NaOD resulted
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1287030-100MG | 04061833850350 |